AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matter.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
